A Registry Study of Biomarkers in Heart Valve Disease
ConditionCardiovascular Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorBeijing Institute of Heart, Lung and Blood Vessel Diseases
About this trial
Valvular Heart Disease, impacting 2.5% of the population, is predominantly observed in the elderly and is on the rise. The primary conditions within this category are Aortic Stenosis and Mitral Regurgitation. These conditions are linked to considerable morbidity and mortality, presenting a formidable challenge in optimizing treatment strategies. Pathophysiology of Valvular Heart Disease remains poorly known. The aim of the present study is to identify biomarkers involved in this disease using multi-omics approaches
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients clinically diagnosed with heart valve disease in Beijing Anzhen Hospital
Disqualifiers
Age < 18 years
Failure to obtain medical records and ultrasound data
Refuse follow-up
Trial population
Patients with heart valve disease accorrding to Inclusion and exclusion criteria.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
All-cause death
whether recidivation happened,whether other related disease happened
Time frame
These data is collected during follow-up visit at 12 months after dischargeSecondary outcomes
1
HF rehospitalization
heart failure related hospitalization within 1 years of discharge
Time frame
These data is collected during follow-up visit at 12 months after dischargeSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov